1. Home
  2. PHM vs ILMN Comparison

PHM vs ILMN Comparison

Compare PHM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PulteGroup Inc.

PHM

PulteGroup Inc.

HOLD

Current Price

$133.66

Market Cap

24.7B

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$132.94

Market Cap

20.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHM
ILMN
Founded
1950
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.7B
20.4B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
PHM
ILMN
Price
$133.66
$132.94
Analyst Decision
Buy
Hold
Analyst Count
12
17
Target Price
$137.67
$124.24
AVG Volume (30 Days)
1.7M
2.3M
Earning Date
04-30-2026
04-30-2026
Dividend Yield
0.76%
N/A
EPS Growth
N/A
170.87
EPS
11.12
5.45
Revenue
N/A
$4,343,000,000.00
Revenue This Year
N/A
$6.56
Revenue Next Year
$3.77
$5.49
P/E Ratio
$12.36
$24.56
Revenue Growth
N/A
N/A
52 Week Low
$88.07
$68.70
52 Week High
$144.50
$155.53

Technical Indicators

Market Signals
Indicator
PHM
ILMN
Relative Strength Index (RSI) 48.47 56.08
Support Level $128.75 $129.86
Resistance Level $141.65 $137.94
Average True Range (ATR) 4.04 4.31
MACD -0.90 1.98
Stochastic Oscillator 19.68 92.83

Price Performance

Historical Comparison
PHM
ILMN

About PHM PulteGroup Inc.

PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: